Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Gefitinib
Iressa · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Iressa | DRUG | - |
Inclusion Criteria: * 18 to 80 years of age. Men with histologically confirmed locally advanced prostatic adenocarcinoma Exclusion Criteria: * No prior treatment for prostate cancer, including surgery, radiotherapy, cryotherapy or thermotherapy. No abnormal laboratory values. No co-existing malig...
Iressa, also known as Gefitinib, is a small molecule being studied for the treatment of locally advanced prostate cancer. It is an investigational drug in Phase 2 clinical development, evaluated in combination with Casodex in a completed trial. The study enrolled 102 male participants aged 18 years and older in Norway.
Iressa is a kinase inhibitor, belonging to the -tinib class of drugs. It targets and inhibits specific kinase enzymes involved in cancer cell growth and proliferation. This mechanism is being explored in the context of locally advanced prostate cancer, where it was tested in combination with Casodex in a Phase 2 clinical trial.
Iressa is developed by AstraZeneca PLC, a multinational pharmaceutical company listed on the stock exchange under the ticker AZN. The drug is being investigated for locally advanced prostate cancer, with a completed Phase 2 clinical trial assessing its efficacy and safety in combination with Casodex.
Iressa is in Phase 2 clinical development for locally advanced prostate cancer. It is an investigational drug, not yet approved for this indication. The Phase 2 trial, NCT00319787, has been completed, and the drug is no longer in active clinical trials for this condition.
Iressa was studied in a single Phase 2 clinical trial, NCT00319787, titled 'Combination Casodex® and Iressa™ in Locally Advanced Prostate Cancer'. This completed trial enrolled 102 participants and was conducted in Norway. The study was randomized, double-blind, and uncontrolled, with a control type of uncontrolled.
Yes, Iressa is the brand name for Gefitinib. The drug is also known by its generic name, Gefitinib. In clinical trials and medical literature, it may be referred to by either name. In the context of locally advanced prostate cancer, it is being investigated under the name Iressa.